$CVRX News
Last published 5d ago
- 5d agoCVRXTrading halt: CVRx, Inc. CS (CVRX), Volatility trading pauseNasdaq Trading HaltsHalted 2026-11-06 09:36:44.616 ET, resumption quote 2026-11-06 09:36:44 ET, resumption trade none.
- 6d agoCVRXCVRx, Inc. - EXHIBIT 99.1Earnings ReleasesForm 8-K - Current report - Item 2.02 Item 9.01
- 6d agoCVRXCVRx Reports Third Quarter 2026 Financial and Operating ResultsGlobeNewswireMINNEAPOLIS, Nov. 05, 2026 (GLOBE NEWSWIRE) -- CVRx, Inc. (NASDAQ:CVRX) ("CVRx"), a commercial-stage medical device company focused on developing, manufacturing and commercializing innovative neuromodulation
- 1w agoCVRXCVRx to Participate in Upcoming Investor ConferencesGlobeNewswireMINNEAPOLIS, Nov. 02, 2026 (GLOBE NEWSWIRE) -- CVRx, Inc. (NASDAQ:CVRX) ("CVRx"), a commercial-stage medical device company focused on developing, manufacturing and commercializing innovative neuromodulation
- 2w agoCVRXCVRx to Report Third Quarter 2026 Financial and Operating Results and Host Conference Call on November 5, 2026GlobeNewswireMINNEAPOLIS, Oct. 22, 2026 (GLOBE NEWSWIRE) -- CVRx, Inc. (NASDAQ:CVRX) ("CVRx"), a commercial-stage medical device company focused on developing, manufacturing and commercializing innovative neuromodulation
- 1mo agoCVRXNYXHVAPOCVRx Appoints John Landry as Chief Financial OfficerGlobeNewswireMINNEAPOLIS, Sept. 21, 2026 (GLOBE NEWSWIRE) -- CVRx, Inc. (NASDAQ:CVRX) ("CVRx"), a commercial-stage medical device company focused on developing, manufacturing and commercializing innovative neuromodulation
- 2mo agoCVRXCVRx Responds to Letter from Pointillist Family OfficeGlobeNewswireMINNEAPOLIS, Aug. 25, 2026 (GLOBE NEWSWIRE) -- CVRx, Inc. (NASDAQ:CVRX) ("CVRx"), a commercial-stage medical device company focused on developing, manufacturing and commercializing innovative neuromodulation
- 2mo agoCVRxJorey Chernett, Owner of More than 5.5% of Outstanding Shares of CVRx, Calls on Board to Begin Immediate Process to Pursue Sale of the Company to a Strategic AcquirerPR NewswireJorey Chernett, Founder of Pointillist Family Office and beneficial owner of more than 5.5% of the outstanding shares of CVRx, Inc. ("CVRx" or the...
- 2mo agoCVRXCVRx Announces Devoted Health Medicare Advantage Coverage Policy for Barostim TherapyGlobeNewswireMINNEAPOLIS, Aug. 24, 2026 (GLOBE NEWSWIRE) -- CVRx, Inc. (NASDAQ:CVRX) ("CVRx"), a commercial-stage medical device company focused on developing, manufacturing and commercializing innovative neuromodulation
- 3mo agoCVRXCG 46TH ANNUAL GROWTH CONFERENCE - CVRX INCEarnings Call TranscriptsMy name is Bill Plovonek. I'm one of the senior medical device analysts here at Canaccord. The format for CVRx is going to be a short presentation followed by Q&A. And today we have the president and CEO, Kevin Hikes, an
- 3mo agoCVRXCG 46TH ANNUAL GROWTH CONFERENCE - CVRX INCEarnings Call TranscriptsMy name is Bill Plovonek. I'm one of the senior medical device analysts here at Canaccord. The format for CVRx is going to be a short presentation followed by Q&A. And today we have the president and CEO, Kevin Hikes, an
- 3mo agoCVRXCVRx Announces Sales Leadership TransitionGlobeNewswireMINNEAPOLIS, Aug. 11, 2026 (GLOBE NEWSWIRE) -- CVRx, Inc. (NASDAQ:CVRX) ("CVRx"), a commercial-stage medical device company focused on developing, manufacturing and commercializing innovative neuromodulation
- 3mo agoCVRXCVRX INVESTIGATION: CVRx, Inc. Investigated for Securities Fraud by Block & Leviton; Investors Should Contact the Firm to Possibly Recover LossesGlobeNewswireBOSTON, Aug. 10, 2026 (GLOBE NEWSWIRE) -- Block & Leviton is investigating CVRx, Inc. (NASDAQ:CVRX) for potential securities law violations. Investors who have lost money in their CVRx, Inc. investment should
- 3mo agoCVRXCVRx Reports Second Quarter 2026 Financial and Operating ResultsGlobeNewswireMINNEAPOLIS, Aug. 06, 2026 (GLOBE NEWSWIRE) -- CVRx, Inc. (NASDAQ:CVRX) ("CVRx"), a commercial-stage medical device company focused on developing, manufacturing and commercializing innovative neuromodulation
- 3mo agoCVRXCVRx to Present at Canaccord Genuity's 46th Annual Growth ConferenceGlobeNewswireMINNEAPOLIS, July 28, 2026 (GLOBE NEWSWIRE) -- CVRx, Inc. (NASDAQ:CVRX) ("CVRx"), a commercial-stage medical device company focused on developing, manufacturing and commercializing innovative neuromodulation
- 3mo agoCVRXCVRx to Report Second Quarter 2026 Financial and Operating Results and Host Conference Call on August 6, 2026GlobeNewswireMINNEAPOLIS, July 23, 2026 (GLOBE NEWSWIRE) -- CVRx, Inc. (NASDAQ:CVRX) ("CVRx"), a commercial-stage medical device company focused on developing, manufacturing and commercializing innovative neuromodulation
- 5mo agoCVRXCVRx Announces Chief Financial Officer TransitionGlobeNewswireMINNEAPOLIS, June 09, 2026 (GLOBE NEWSWIRE) -- CVRx, Inc. (NASDAQ:CVRX) ("CVRx"), a commercial-stage medical device company focused on developing, manufacturing and commercializing innovative neuromodulation solutions
- 5mo agoCVRXCVRx to Present at the Goldman Sachs 47th Annual Global Healthcare ConferenceGlobeNewswireMINNEAPOLIS, May 27, 2026 (GLOBE NEWSWIRE) -- CVRx, Inc. (NASDAQ:CVRX) ("CVRx"), a commercial-stage medical device company focused on developing, manufacturing and commercializing innovative neuromodulation solutions
- 5mo agoCVRXCVRx to Present at the William Blair 46th Annual Growth Stock ConferenceGlobeNewswireMINNEAPOLIS, May 20, 2026 (GLOBE NEWSWIRE) -- CVRx, Inc. (NASDAQ:CVRX) ("CVRx"), a commercial-stage medical device company focused on developing, manufacturing and commercializing innovative neuromodulation solutions
- 6mo agoCVRXCVRx Announces Humana Medicare Advantage Coverage Policy for Barostim TherapyGlobeNewswireMINNEAPOLIS, May 14, 2026 (GLOBE NEWSWIRE) -- CVRx, Inc. (NASDAQ:CVRX) ("CVRx"), a commercial-stage medical device company focused on developing, manufacturing and commercializing innovative neuromodulation solutions
- 6mo agoCVRXCVRx Q1 2026 Earnings CallCVRX INCEarnings Call TranscriptsGreetings and welcome to the CVRX Q1, 2026 earnings call. At this time, all participants are in a listen-only mode. A brief question and answer session will follow the formal presentation. Should anyone require operator
- 6mo agoCVRXCVRx Reports First Quarter 2026 Financial and Operating ResultsGlobeNewswireMINNEAPOLIS, May 11, 2026 (GLOBE NEWSWIRE) -- CVRx, Inc. (NASDAQ:CVRX) ("CVRx"), a commercial-stage medical device company focused on developing, manufacturing and commercializing innovative neuromodulation
- 6mo agoCVRXCVRx Announces First Patient Enrollment in BENEFIT-HF, a Landmark Heart Failure Trial Evaluating Barostim in Significantly Expanded PopulationGlobeNewswireMINNEAPOLIS, May 04, 2026 (GLOBE NEWSWIRE) -- CVRx, Inc. (NASDAQ:CVRX), a medical device company focused on developing, manufacturing and commercializing innovative neuromodulation solutions for patients with
- 6mo agoCVRXCVRx to Report First Quarter 2026 Financial and Operating Results and Host Conference Call on May 11, 2026GlobeNewswireMINNEAPOLIS, April 27, 2026 (GLOBE NEWSWIRE) -- CVRx, Inc. (NASDAQ:CVRX) ("CVRx"), a commercial-stage medical device company focused on developing, manufacturing and commercializing innovative neuromodulation
- 6mo agoAXGNCVRXCVRx Announces Nomination of Michael Dale for Election to the Board of DirectorsGlobeNewswireMINNEAPOLIS, April 20, 2026 (GLOBE NEWSWIRE) -- CVRx, Inc. (NASDAQ:CVRX), a medical device company focused on developing, manufacturing and commercializing innovative neuromodulation solutions for patients with
- 7mo agoCVRXCVRx Reports Preliminary First Quarter 2026 Financial ResultsGlobeNewswireDelivered strong topline performance with first quarter revenue expected to be $14.7 million to $14.8 million, approximately 20% growth compared to first quarter of 2025Early data in 2026 shows an increase in the 30-day
- 8mo agoCVRXCVRx Announces Late-Breaking Data and Scientific Presentations Highlighting Barostim Outcomes at the THT 2026 Annual MeetingGlobeNewswireMINNEAPOLIS, March 02, 2026 (GLOBE NEWSWIRE) -- CVRx, Inc. (NASDAQ:CVRX), a medical device company focused on developing, manufacturing and commercializing innovative neuromodulation solutions for patients with
- 9mo agoCVRXCVRx Reports Fourth Quarter and Full Year 2025 Financial and Operating ResultsGlobeNewswireMINNEAPOLIS, Feb. 12, 2026 (GLOBE NEWSWIRE) -- CVRx, Inc. (NASDAQ:CVRX) ("CVRx"), a commercial-stage medical device company focused on developing, manufacturing and commercializing innovative neuromodulation
- 9mo agoCVRXCVRx to Report Fourth Quarter 2025 Financial and Operating Results and Host Conference Call on February 12, 2026GlobeNewswireMINNEAPOLIS, Jan. 29, 2026 (GLOBE NEWSWIRE) -- CVRx, Inc. (NASDAQ:CVRX) ("CVRx"), a commercial-stage medical device company focused on developing, manufacturing and commercializing innovative neuromodulation
- 9mo agoCVRXCVRx Announces Initiation of BENEFIT-HF, a Landmark Heart Failure Trial Evaluating Barostim in Significantly Expanded PopulationGlobeNewswireMINNEAPOLIS, Jan. 22, 2026 (GLOBE NEWSWIRE) -- CVRx, Inc. (NASDAQ:CVRX), a medical device company focused on developing, manufacturing and commercializing innovative neuromodulation solutions for patients with
- 10mo agoCVRXWolf Popper LLP Announces Investigation on Behalf of CVRx, Inc. InvestorsGlobeNewswireNEW YORK, Jan. 13, 2026 (GLOBE NEWSWIRE) -- Wolf Popper LLP is investigating potential claims on behalf of purchasers of CVRx, Inc. ("CVRx") common stock (NASDAQ:CVRX). CVRx is a medical device company. CVRx's
- 10mo agoCVRXCVRx Reports Preliminary Fourth Quarter and Fiscal Year 2025 Financial Results and Issues Fiscal 2026 GuidanceGlobeNewswireFourth quarter revenue expected to be $15.9 million to $16.1 million, representing growth of 4% to 5%Full year revenue expected to be $56.5 million to $56.7 million, representing growth of 10% to 11%Fiscal 2026 revenue
- 10mo agoCVRXCVRx Announces Implementation of New Category I CPT Codes for Barostim TherapyGlobeNewswireMINNEAPOLIS, Jan. 06, 2026 (GLOBE NEWSWIRE) -- CVRx, Inc. (NASDAQ:CVRX) ("CVRx"), a commercial-stage medical device company focused on developing, manufacturing and commercializing innovative neuromodulation solutions
- 10mo agoCVRXCVRx to Present at the 44th Annual J.P. Morgan Healthcare ConferenceGlobeNewswireMINNEAPOLIS, Dec. 22, 2025 (GLOBE NEWSWIRE) -- CVRx, Inc. (NASDAQ:CVRX) ("CVRx"), a commercial-stage medical device company focused on developing, manufacturing and commercializing innovative neuromodulation
- 11mo agoCVRXCVRx to Participate at the Piper Sandler 37th Annual Healthcare ConferenceGlobeNewswireMINNEAPOLIS, Nov. 19, 2025 (GLOBE NEWSWIRE) -- CVRx, Inc. (NASDAQ:CVRX) ("CVRx"), a commercial-stage medical device company focused on developing, manufacturing and commercializing innovative neuromodulation
- 1y agoCVRXCVRx Reports Third Quarter 2025 Financial and Operating ResultsGlobeNewswireMINNEAPOLIS, Nov. 05, 2025 (GLOBE NEWSWIRE) -- CVRx, Inc. (NASDAQ:CVRX) ("CVRx"), a commercial-stage medical device company focused on developing, manufacturing and commercializing innovative neuromodulation
- 1y agoCVRXCVRx to Present at the Jefferies Global Healthcare Conference in LondonGlobeNewswireMINNEAPOLIS, Nov. 04, 2025 (GLOBE NEWSWIRE) -- CVRx, Inc. (NASDAQ:CVRX) ("CVRx"), a commercial-stage medical device company focused on developing, manufacturing and commercializing innovative neuromodulation
- 1y agoCVRXCVRx to Report Third Quarter 2025 Financial and Operating Results and Host Conference Call on Nov. 5, 2025GlobeNewswireMINNEAPOLIS, Oct. 22, 2025 (GLOBE NEWSWIRE) -- CVRx, Inc. (NASDAQ:CVRX) ("CVRx"), a commercial-stage medical device company focused on developing, manufacturing and commercializing innovative neuromodulation
- 1y agoCVRXCVRx, Inc. (CVRX) Q2 2025 Earnings Call TranscriptEarnings Call Transcripts
- 1y agoCVRXCVRx Reports Second Quarter 2025 Financial and Operating ResultsGlobeNewswireMINNEAPOLIS, Aug. 04, 2025 (GLOBE NEWSWIRE) -- CVRx, Inc. (NASDAQ:CVRX) ("CVRx"), a commercial-stage medical device company focused on developing, manufacturing and commercializing innovative neuromodulation
- 1y agoCVRXCVRx to Present at the Canaccord Genuity 45th Annual Growth ConferenceGlobeNewswireMINNEAPOLIS, July 29, 2025 (GLOBE NEWSWIRE) -- CVRx, Inc. (NASDAQ:CVRX) ("CVRx"), a commercial-stage medical device company focused on developing, manufacturing and commercializing innovative neuromodulation
- 1y agoCVRXCVRx to Report Second Quarter 2025 Financial and Operating Results and Host Conference Call on August 4, 2025GlobeNewswireMINNEAPOLIS, July 21, 2025 (GLOBE NEWSWIRE) -- CVRx, Inc. (NASDAQ:CVRX) ("CVRx"), a commercial-stage medical device company focused on developing, manufacturing and commercializing innovative neuromodulation
- 1y agoCVRXCVRx Announces Positive News on Outpatient Payment for BarostimGlobeNewswireMINNEAPOLIS, July 16, 2025 (GLOBE NEWSWIRE) -- CVRx, Inc. (NASDAQ:CVRX) ("CVRx"), a commercial-stage medical device company, announced today that the Centers for Medicare and Medicaid Services (CMS) has proposed to
- 1y agoCVRXCVRx to Present at the William Blair 45th Annual Growth Stock ConferenceGlobeNewswireMINNEAPOLIS, May 28, 2025 (GLOBE NEWSWIRE) -- CVRx, Inc. (NASDAQ:CVRX) ("CVRx"), a commercial-stage medical device company focused on developing, manufacturing and commercializing innovative neuromodulation
- 1y agoCVRXCVRx Reports First Quarter 2025 Financial and Operating ResultsGlobeNewswireMINNEAPOLIS, May 08, 2025 (GLOBE NEWSWIRE) -- CVRx, Inc. (NASDAQ:CVRX) ("CVRx"), a commercial-stage medical device company focused on developing, manufacturing and commercializing innovative neuromodulation
- 1y agoCVRXCVRx to Report First Quarter 2025 Financial and Operating Results and Host Conference Call on May 8, 2025GlobeNewswireMINNEAPOLIS, April 24, 2025 (GLOBE NEWSWIRE) -- CVRx, Inc. (NASDAQ:CVRX) ("CVRx"), a commercial-stage medical device company, today announced that it plans to release first quarter 2025 financial and operating
- 1y agoCVRXCVRx Reports Preliminary First Quarter 2025 Financial ResultsGlobeNewswireMINNEAPOLIS, April 07, 2025 (GLOBE NEWSWIRE) -- CVRx, Inc. (NASDAQ:CVRX) ("CVRx"), a commercial-stage medical device company, today announced certain preliminary unaudited first quarter 2025 revenue results.
- 1y agoCVRXCVRx announces new real-world evidence demonstrating significant reductions in healthcare utilization with BarostimGlobeNewswireMINNEAPOLIS, Feb. 12, 2025 (GLOBE NEWSWIRE) -- CVRx, Inc. (NASDAQ:CVRX) ("CVRx"), a commercial-stage medical device company, announced today the presentation of new real-world evidence at the Technology and Heart
- 1y agoCVRXCVRx Reports Fourth Quarter and Full Year 2024 Financial and Operating ResultsGlobeNewswireMINNEAPOLIS, Feb. 04, 2025 (GLOBE NEWSWIRE) -- CVRx, Inc. ("CVRx"), a commercial-stage medical device company focused on developing, manufacturing and commercializing innovative neuromodulation solutions for
- 1y agoCVRXCVRx to Report Fourth Quarter 2024 Financial and Operating Results and Host Conference Call on February 4, 2025GlobeNewswireMINNEAPOLIS, Jan. 21, 2025 (GLOBE NEWSWIRE) -- CVRx, Inc. (NASDAQ:CVRX) ("CVRx"), a commercial-stage medical device company focused on developing, manufacturing and commercializing Barostim™, an innovative